Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
PR Newswire
PORTAGE, Mich., Oct. 14, 2026
- Stryker has received FDA 510(k) clearance for Sonopet® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform.
- Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.
- Customers gain access to advanced technologies including RISE and Pulse Control, supporting streamlined workflows and integration across surgical settings.
PORTAGE, Mich., Oct. 14, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that Sonopet 3, its latest ultrasonic bone and soft tissue removal platform, has received 510(k) clearance from the U.S. Food and Drug Administration.
Developed with input from hundreds of surgeons, Sonopet 3 is designed to deliver enhanced power, precision and versatility in a single platform for tissue removal. Surgeon collaboration directly shaped the new platform, informing key improvements in performance, workflow efficiency and clinical priorities.
"At Stryker, innovation begins with listening to our customers," said Mitch Foley, vice president and general manager of Stryker's Neurosurgical business. "Every major advancement in Sonopet 3 can be attributed to surgeon feedback, and together we're elevating the standard in neurosurgery. They told us they wanted more power, improved ergonomics and enhanced integration, helping them perform with confidence in demanding surgical environments."
In addition to performance enhancements, Sonopet 3 provides access to the platform's latest technologies, including RISE, a Reimagined Integrated Surgical Experience for a connected surgical workflow, and Pulse Control, which provides an added ability to regulate the resection of hard and soft tissues. Together, these advancements help support integration across surgical workflows.
The first clinical cases using Sonopet 3 are expected to begin in October, with a full commercial launch anticipated later this fall.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Media contact
Stryker
Jenny Braga
Senior Director, External Affairs
jenny.braga@stryker.com
SOURCE Stryker
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States